Celcuity
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 55
- Market Cap
- -
- Introduction
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Conditions
- Breast Cancer
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 674
- Registration Number
- NCT06757634
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸UCLA Hematology Oncology Ventura, Los Angeles, California, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Diseases, MaleProstatic DiseaseProstatic Neoplasms, Castration-ResistantUrogenital Diseases, MaleProstate Cancer
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 54
- Registration Number
- NCT06190899
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 701
- Registration Number
- NCT05501886
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Arizona Oncology (US Oncology/McKesson) - Goodyear, Goodyear, Arizona, United States
🇺🇸St. Bernards Medical Center, Jonesboro, Arkansas, United States
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
- Conditions
- Breast Neoplasm Malignant Female
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Celcuity Inc
- Registration Number
- NCT05134922
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 141
- Registration Number
- NCT02684032
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc., Riverside, California, United States
🇺🇸Keck Hospital of USC - Norris Healthcare Center (HC3), Los Angeles, California, United States
News
Celcuity's Gedatolisib Shows Promising Results in Prostate and Breast Cancer Trials
Celcuity reported a 66% six-month radiographic progression-free survival rate for gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer patients.
Gedatolisib Shows Promising 77-Month Overall Survival in Advanced Breast Cancer Phase 1b Trial
Phase 1b trial demonstrates gedatolisib combination therapy achieved 77.3 months median overall survival in treatment-naïve HR+/HER2- advanced breast cancer patients.
Celcuity's Gedatolisib Projected to Reach $155M Annual Revenue by 2034 for Breast Cancer Treatment
Gedatolisib, a dual PI3K/mTOR inhibitor developed by Celcuity, shows promising market potential with projected annual revenue of $155 million by 2034 in the US market.